Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2106 + 5-FU/FA in Metastatic Colorectal Cancer
NCT00291785Phase 2Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2004
- Primary completion
- Aug 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polyglutamate camptothecin in metastatic colorectal cancer (mCRC), sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicities and 2 more. Started Jan 2004; status: completed.
02
Drugs
polyglutamate camptothecin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00291785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291785.